Cadrenal Therapeutics (CVKD) to Release Quarterly Earnings on Thursday

Cadrenal Therapeutics (NASDAQ:CVKD) is expected to be announcing its Q4 2025 results before the market opens on Thursday, March 12th. Analysts expect Cadrenal Therapeutics to post earnings of ($1.21) per share for the quarter. Investors can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:00 PM ET.

Cadrenal Therapeutics Price Performance

Shares of Cadrenal Therapeutics stock opened at $8.00 on Wednesday. Cadrenal Therapeutics has a 12 month low of $4.91 and a 12 month high of $20.39. The stock has a market capitalization of $18.72 million, a price-to-earnings ratio of -1.00 and a beta of 1.04. The firm’s fifty day simple moving average is $7.19 and its 200-day simple moving average is $10.21.

Insider Activity at Cadrenal Therapeutics

In other news, CFO Matthew K. Szot sold 9,933 shares of the firm’s stock in a transaction that occurred on Monday, December 29th. The shares were sold at an average price of $6.97, for a total transaction of $69,233.01. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 26.09% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Cadrenal Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. DRW Securities LLC acquired a new stake in Cadrenal Therapeutics during the 4th quarter valued at $171,000. Geode Capital Management LLC boosted its stake in shares of Cadrenal Therapeutics by 14.3% during the fourth quarter. Geode Capital Management LLC now owns 14,528 shares of the company’s stock valued at $98,000 after acquiring an additional 1,818 shares during the last quarter. Citadel Advisors LLC purchased a new stake in Cadrenal Therapeutics during the 3rd quarter worth about $274,000. Finally, JPMorgan Chase & Co. acquired a new position in Cadrenal Therapeutics in the 3rd quarter valued at about $103,000. Hedge funds and other institutional investors own 7.92% of the company’s stock.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cadrenal Therapeutics in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Cadrenal Therapeutics has an average rating of “Hold” and an average target price of $32.00.

Cadrenal Therapeutics Company Profile

Cadrenal Therapeutics, Inc operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.